Patient-derived tumor xenografts: transforming clinical samples into mouse models

doi:10.1158/0008-5472.CAN-13-1069

Review

. 2013 Sep 1;73(17):5315-9.

doi: 10.1158/0008-5472.CAN-13-1069. Epub 2013 Jun 3.

Patient-derived tumor xenografts: transforming clinical samples into mouse models

Despina Siolas¹, Gregory J Hannon

Affiliations

Affiliation

¹ New York University Cancer Institute; and Watson School of Biological Sciences, Howard Hughes Medical Institute Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY 11742, USA.

PMID: 23733750
PMCID: PMC3766500
DOI: 10.1158/0008-5472.CAN-13-1069

Free PMC article

Review

Patient-derived tumor xenografts: transforming clinical samples into mouse models

Despina Siolas et al. Cancer Res. 2013.

Free PMC article

. 2013 Sep 1;73(17):5315-9.

doi: 10.1158/0008-5472.CAN-13-1069. Epub 2013 Jun 3.

Authors

Despina Siolas¹, Gregory J Hannon

Affiliation

¹ New York University Cancer Institute; and Watson School of Biological Sciences, Howard Hughes Medical Institute Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY 11742, USA.

PMID: 23733750
PMCID: PMC3766500
DOI: 10.1158/0008-5472.CAN-13-1069

Abstract

Tumor graft models (also known as patient-derived xenografts or PDX) are based on the transfer of primary tumors directly from the patient into an immunodeficient mouse. Because PDX mice are derived from human tumors, they offer a tool for developing anticancer therapies and personalized medicine for patients with cancer. In addition, these models can be used to study metastasis and tumor genetic evolution. This review examines the development, challenges, and broad use of these attractive preclinical models.

PubMed Disclaimer

Cited by

Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine.
Qu S, Xu R, Yi G, Li Z, Zhang H, Qi S, Huang G. Qu S, et al. Mol Biomed. 2024 Feb 12;5(1):6. doi: 10.1186/s43556-023-00165-9. Mol Biomed. 2024. PMID: 38342791 Free PMC article. Review.
Experimental models for cancer brain metastasis.
Liu Z, Dong S, Liu M, Liu Y, Ye Z, Zeng J, Yao M. Liu Z, et al. Cancer Pathog Ther. 2023 Oct 29;2(1):15-23. doi: 10.1016/j.cpt.2023.10.005. eCollection 2024 Jan. Cancer Pathog Ther. 2023. PMID: 38328712 Free PMC article. Review.
Patient-derived organoids as personalized avatars and a potential immunotherapy model in cervical cancer.
Huang H, Pan Y, Huang J, Zhang C, Liao Y, Du Q, Qin S, Chen Y, Tan H, Chen M, Xu M, Xia M, Liu Y, Li J, Liu T, Zou Q, Zhou Y, Yuan L, Wang W, Liang Y, Pan CY, Liu J, Yao S. Huang H, et al. iScience. 2023 Oct 12;26(11):108198. doi: 10.1016/j.isci.2023.108198. eCollection 2023 Nov 17. iScience. 2023. PMID: 38026204 Free PMC article.
Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy.
Choi D, Gonzalez-Suarez AM, Dumbrava MG, Medlyn M, de Hoyos-Vega JM, Cichocki F, Miller JS, Ding L, Zhu M, Stybayeva G, Gaspar-Maia A, Billadeau DD, Ma WW, Revzin A. Choi D, et al. Adv Sci (Weinh). 2024 Feb;11(5):e2303088. doi: 10.1002/advs.202303088. Epub 2023 Nov 29. Adv Sci (Weinh). 2024. PMID: 38018486 Free PMC article.
Introduction of Androgen Receptor Targeting shRNA Inhibits Tumor Growth in Patient-Derived Prostate Cancer Xenografts.
Thomas PB, Alinezhad S, Joshi A, Sweeney K, Tse BWC, Tevz G, McPherson S, Nelson CC, Williams ED, Vela I. Thomas PB, et al. Curr Oncol. 2023 Oct 24;30(11):9437-9447. doi: 10.3390/curroncol30110683. Curr Oncol. 2023. PMID: 37999103 Free PMC article.

See all "Cited by" articles

References

1. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer research. 2009;69:3364–3373. - PMC - PubMed
1. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer research. 2006;66:3351–3354. discussion 4. - PubMed
1. Boedigheimer MJ, Freeman DJ, Kiaei P, Damore MA, Radinsky R. Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models. Neoplasia. 2013;15:125–132. - PMC - PubMed
1. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nature protocols. 2009;4:1670–1680. - PMC - PubMed
1. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clinical pharmacology and therapeutics. 2009;85:217–221. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations
- scite Smart Citations

[1] Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer research. 2009;69:3364–3373. - PMC - PubMed

[2] Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer research. 2009;69:3364–3373. - PMC - PubMed

[3] Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer research. 2006;66:3351–3354. discussion 4. - PubMed

[4] Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer research. 2006;66:3351–3354. discussion 4. - PubMed

[5] Boedigheimer MJ, Freeman DJ, Kiaei P, Damore MA, Radinsky R. Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models. Neoplasia. 2013;15:125–132. - PMC - PubMed

[6] Boedigheimer MJ, Freeman DJ, Kiaei P, Damore MA, Radinsky R. Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models. Neoplasia. 2013;15:125–132. - PMC - PubMed

[7] Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nature protocols. 2009;4:1670–1680. - PMC - PubMed

[8] Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nature protocols. 2009;4:1670–1680. - PMC - PubMed

[9] Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clinical pharmacology and therapeutics. 2009;85:217–221. - PubMed

[10] Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clinical pharmacology and therapeutics. 2009;85:217–221. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Patient-derived tumor xenografts: transforming clinical samples into mouse models

Affiliation

Patient-derived tumor xenografts: transforming clinical samples into mouse models

Authors

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources